https://www.mynewsdesk.com/se/csl-behring Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/se/csl-behring https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Tue, 17 Mar 2026 08:25:34 +0100 The National “New Methods” decision forum in Norway yesterday announced a positive recommendation for the reimbursement of HEMGENIX® (etranacogene dezaparvovec) for the treatment of patients with the rare blood clotting disorder haemophilia B, paving the way for the finalization of a commercial contract with Sykehusinnkjøp, the Norwegian procurement authority. https://www.mynewsdesk.com/se/csl-behring/pressreleases/the-national-new-methods-decision-forum-in-norway-recommends-csls-gene-therapy-hemgenix-r-for-adults-with-severe-or-moderately-severe-haemophilia-b-without-a-history-of-factor-ix-inhibitors-3437889?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/the-national-new-methods-decision-forum-in-norway-recommends-csls-gene-therapy-hemgenix-r-for-adults-with-severe-or-moderately-severe-haemophilia-b-without-a-history-of-factor-ix-inhibitors-3437889?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Wed, 28 Jan 2026 09:11:54 +0100 Tandvårds- och läkemedelsförmånsverket (TLV) har meddelat att ANDEMBRY® ska ingå i läkemedelsförmånerna från och med den 1 februari 2026. Subventionen är begränsad till rutinmässig prevention av recidiverande anfall av hereditärt angioödem (HAE) hos patienter i åldern 12 år och äldre med svår sjukdomsbild och minst fyra HAE-anfall i månaden. https://www.mynewsdesk.com/se/csl-behring/pressreleases/andembry-garadacimab-faar-subvention-foer-foerebyggande-av-aaterkommande-hae-anfall-vid-svaar-sjukdom-3429310?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/andembry-garadacimab-faar-subvention-foer-foerebyggande-av-aaterkommande-hae-anfall-vid-svaar-sjukdom-3429310?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Tue, 09 Dec 2025 08:31:20 +0100 Global biopharma leader CSL (ASX:CSL) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec) in adults living with moderate to severe haemophilia B. Published in the New England Journal of Medicine (NEJM). https://www.mynewsdesk.com/se/csl-behring/pressreleases/data-published-in-the-new-england-journal-of-medicine-confirm-the-long-term-durability-and-safety-of-hemgenix-r-etranacogene-dezaparvovec-over-five-years-3420368?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/data-published-in-the-new-england-journal-of-medicine-confirm-the-long-term-durability-and-safety-of-hemgenix-r-etranacogene-dezaparvovec-over-five-years-3420368?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Thu, 04 Dec 2025 08:57:46 +0100 Sverige ligger under EU-snittet i patienters tillgång till behandlingar för sällsynta sjukdomar och patienter i 20 europeiska länder har tillgång till fler särläkemedel. Resultatbaserade avtal där betalning kopplas till faktisk klinisk effekt kan minska ekonomiska risker och samtidigt bidra till kostnadsbesparingar och effektivare vård. Flera länder, som Danmark, har redan infört sådana modeller. https://www.mynewsdesk.com/se/csl-behring/pressreleases/nya-terapier-kraever-nya-betalningsmodeller-csl-deltar-vid-new-horizons-in-biologics-och-bioprocessing-i-stockholm-3419951?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/nya-terapier-kraever-nya-betalningsmodeller-csl-deltar-vid-new-horizons-in-biologics-och-bioprocessing-i-stockholm-3419951?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Tue, 11 Feb 2025 08:34:37 +0100 94% of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment. Mean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX® in the treatment of haemophilia B. https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behrings-gene-therapy-hemgenix-etranacogene-dezaparvovec-four-years-post-infusion-data-continue-to-show-sustained-efficacy-and-safety-in-adults-with-haemophilia-b-3369012?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behrings-gene-therapy-hemgenix-etranacogene-dezaparvovec-four-years-post-infusion-data-continue-to-show-sustained-efficacy-and-safety-in-adults-with-haemophilia-b-3369012?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Tue, 28 Jan 2025 08:31:27 +0100 Helena Bragd is the new General Manager of CSL Behring Nordic Region – Sweden, Denmark, Norway, Finland, and Iceland. CSL Behring is a global biotherapeutics leader driven by our promise to save lives. https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behring-appoints-helena-bragd-as-new-general-manager-for-the-nordic-region-3366431?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behring-appoints-helena-bragd-as-new-general-manager-for-the-nordic-region-3366431?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Tue, 21 Jan 2025 08:26:55 +0100 CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is the first one-time gene therapy to be approved in Europe for the treatment of adults with severe and moderately severe haemophilia B. https://www.mynewsdesk.com/se/csl-behring/pressreleases/first-patients-treated-with-hemgenix-r-etranacogene-dezaparvovec-gene-therapy-for-haemophilia-b-in-denmark-3364959?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/first-patients-treated-with-hemgenix-r-etranacogene-dezaparvovec-gene-therapy-for-haemophilia-b-in-denmark-3364959?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Tue, 29 Oct 2024 09:34:27 +0100 CSL Behring today announced that an outcome-based agreement has been reached with Amgros, the Danish procurement authority, for the national reimbursement of HEMGENIX® in Denmark. Denmark is the first country in the Nordic region to reimburse HEMGENIX® under such a performance-based model, in which the regions only incur costs if the gene therapy proves effective over an agreed long-term period. https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behring-signs-milestone-commercial-agreement-with-amgros-to-fund-haemophilia-b-gene-therapy-hemgenix-in-denmark-3351393?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behring-signs-milestone-commercial-agreement-with-amgros-to-fund-haemophilia-b-gene-therapy-hemgenix-in-denmark-3351393?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Tue, 25 Jun 2024 08:33:05 +0200 CSL Behring today announced that a positive recommendation for reimbursement of HEMGENIX has been released by the Danish Medicines Council for the treatment of patients with rare blood clotting disorder, haemophilia B opening the way to finalize a commercial contract with Amgros, the Danish procurement authority.1 Denmark is the first country in the Nordics to reimburse HEMGENIX. https://www.mynewsdesk.com/se/csl-behring/pressreleases/the-danish-medicines-council-recommends-csl-behrings-gene-therapy-hemgenix-r-for-adults-with-severe-or-moderately-severe-haemophilia-b-3331735?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/the-danish-medicines-council-recommends-csl-behrings-gene-therapy-hemgenix-r-for-adults-with-severe-or-moderately-severe-haemophilia-b-3331735?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Mon, 15 Apr 2024 08:57:56 +0200 Den 17 april är det Världshemofilidagen som i år har fokus på rättvis tillgång till behandling för alla med blödarsjuka. CSL Behring är ett globalt bioteknikföretag som drivs av löftet att rädda och förbättra människors liv. Forskningen inom hemofili har gjort stora framsteg under de senaste åren som har lett till nya behandlingsformer. https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behring-uppmaerksammar-vaerldshemofilidagen-och-alla-som-lever-med-bloedarsjuka-3316471?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behring-uppmaerksammar-vaerldshemofilidagen-och-alla-som-lever-med-bloedarsjuka-3316471?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Fri, 15 Dec 2023 13:45:00 +0100 These regulatory milestones bring CSL one step closer to delivering on our promise to patients with a first-in-class recombinant monoclonal antibody for people living with HAE, a community CSL has been serving for over 40 years, in the US and European Union. https://www.mynewsdesk.com/se/csl-behring/pressreleases/csls-garadacimab-a-first-in-class-factor-xiia-inhibitor-receives-fda-and-ema-filing-acceptance-3293499?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/csls-garadacimab-a-first-in-class-factor-xiia-inhibitor-receives-fda-and-ema-filing-acceptance-3293499?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Thu, 13 Apr 2023 10:23:40 +0200 Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema. https://www.mynewsdesk.com/se/csl-behring/pressreleases/the-lancet-publishes-pivotal-phase-3-data-on-csls-first-in-class-garadacimab-for-hae-3245772?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/the-lancet-publishes-pivotal-phase-3-data-on-csls-first-in-class-garadacimab-for-hae-3245772?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Tue, 21 Feb 2023 08:28:06 +0100 The European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B in adults without a history of Factor IX inhibitors. In the ongoing clinical trial, HEMGENIX® reduced the rate of annual bleeds with a single infusion. https://www.mynewsdesk.com/se/csl-behring/pressreleases/first-gene-therapy-for-hemophilia-b-csls-hemgenix-approved-by-the-european-commission-3234913?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/first-gene-therapy-for-hemophilia-b-csls-hemgenix-approved-by-the-european-commission-3234913?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Mon, 28 Mar 2022 16:25:00 +0200 Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with hemophilia B. MAA filing is supported by the phase 3 HOPE-B study which demonstrated durable and sustained therapeutic effect after a single infusion. https://www.mynewsdesk.com/se/csl-behring/pressreleases/european-medicines-agency-commences-review-of-novel-gene-therapy-candidate-etranacogene-dezaparvovec-for-people-with-hemophilia-b-3171893?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/european-medicines-agency-commences-review-of-novel-gene-therapy-candidate-etranacogene-dezaparvovec-for-people-with-hemophilia-b-3171893?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Fri, 04 Feb 2022 16:36:20 +0100 Data from the largest gene therapy study in Hemophilia B to date shows that etranacogene dezaparvovec is statistically superior in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy. Following a single administration of etranacogene dezaparvovec, participants maintained stable Factor IX (FIX) activity through 18 months. https://www.mynewsdesk.com/se/csl-behring/pressreleases/final-analysis-of-pivotal-hope-b-study-demonstrates-durable-and-sustained-therapeutic-effect-of-etranacogene-dezaparvovec-gene-therapy-in-hemophilia-b-data-presented-at-eahad-2022-3159985?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/final-analysis-of-pivotal-hope-b-study-demonstrates-durable-and-sustained-therapeutic-effect-of-etranacogene-dezaparvovec-gene-therapy-in-hemophilia-b-data-presented-at-eahad-2022-3159985?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Wed, 15 Dec 2021 15:17:39 +0100 CSL Behring today announced that the European Medicines Agency has granted its approval for an accelerated assessment request for etranacogene dezaparvovec Marketing Authorisation Application (MAA). Etranacogene dezaparvovec is an investigational gene therapy for people with haemophilia B, a life-threatening bleeding disorder, and is currently being studied in the Phase 3 HOPE-B clinical trial. https://www.mynewsdesk.com/se/csl-behring/pressreleases/ema-grants-accelerated-assessment-for-csl-behrings-haemophilia-b-gene-therapy-3151238?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/ema-grants-accelerated-assessment-for-csl-behrings-haemophilia-b-gene-therapy-3151238?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Tue, 30 Nov 2021 11:00:32 +0100 The CSL Behring Nordic von Willebrand Scholarship is awarded every two years. Dr Vuokko Nummi receives the 2020 scholarship for research on characterization of microcirculation and associations to angiodysplasia in von Willebrand disease. https://www.mynewsdesk.com/se/csl-behring/pressreleases/dr-vuokko-nummi-at-helsinki-university-hospital-receives-the-csl-behring-nordic-von-willebrand-scholarship-3147411?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/dr-vuokko-nummi-at-helsinki-university-hospital-receives-the-csl-behring-nordic-von-willebrand-scholarship-3147411?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Thu, 06 May 2021 16:01:00 +0200 Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding. uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring. https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behring-announces-closing-of-global-commercialization-and-license-agreement-with-uniqure-for-etranacogene-dezaparvovec-3097926?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/pressreleases/csl-behring-announces-closing-of-global-commercialization-and-license-agreement-with-uniqure-for-etranacogene-dezaparvovec-3097926?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Wed, 11 Nov 2020 10:23:00 +0100 ​Vi pratar med tjugotreåriga Sara som lever med den ovanliga blödardiagnosen ITP (immunologisk trombocytopeni) som drabbar cirka 3 av 100 000 personer varje år. Sara berättar om den okunskap hon stött på i livet och hur den påverkat henne. https://www.mynewsdesk.com/se/csl-behring/news/nytt-avsnitt-av-bloedigt-vaerre-okunskap-och-foerdomar-418313?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/news/nytt-avsnitt-av-bloedigt-vaerre-okunskap-och-foerdomar-418313?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring Thu, 08 Oct 2020 10:27:00 +0200 Under åren har det hunnit bli 20 olika avsnitt där vi lyfter frågor, sprider kunskap och sticker hål på en del fördomar om blödarsjuka. Medverkar gör unga och gamla med blödarsjuka, föräldrar, läkare och forskare för att samtala och söka svar. https://www.mynewsdesk.com/se/csl-behring/news/podcasten-bloedigt-vaerre-firar-20-avsnitt-414334?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/csl-behring/news/podcasten-bloedigt-vaerre-firar-20-avsnitt-414334?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news CSL Behring